Reduction in advanced glycation end products by ACE inhibitor in diabetic cardiomyopathy model

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Asian Biomedicine

• Publication date

  2013-03-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.5372/1905-7415.0701.148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up‐regulation contribute to the onset of diabetic cardiomyopathy

  2009cited by this paper
• Mechanism of High Glucose–Induced Angiotensin II Production in Rat Vascular Smooth Muscle Cells

  2007influential reference
• Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy

  2007cited by this paper
• Advanced Glycation End Products Activate a Chymase-Dependent Angiotensin II–Generating Pathway in Diabetic Complications

  2006cited by this paper
• Diabetic cardiomyopathy: the search for a unifying hypothesis.

  2006cited by this paper
• The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.

  2004cited by this paper
• Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat

  2004cited by this paper
• Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: A short review

  2004cited by this paper
• Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

  2004cited by this paper
• Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat

  2003cited by this paper
• Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms.

  2002cited by this paper
• Angiotensin-Converting Enzyme Inhibitor Helps Prevent Late Remodeling After Left Ventricular Aneurysm Repair in Rats

  2002cited by this paper
• Advanced glycation end product precursors impair epidermal growth factor receptor signaling.

  2002cited by this paper
• Dose-Dependent Regulation of NAD(P)H Oxidase Expression by Angiotensin II in Human Endothelial Cells: Protective Effect of Angiotensin II Type 1 Receptor Blockade in Patients With Coronary Artery Disease

  2002cited by this paper
• Angiotensin II as a renal growth factor.

  2001cited by this paper
• The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect.

  2000cited by this paper
• The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells*

  2000cited by this paper
• Coronary Composition and Macrophage Infiltration in Atherectomy Specimens From Patients With Diabetes Mellitus

  2000cited by this paper
• Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries.

  2000cited by this paper
• Myocyte Death in Streptozotocin-Induced Diabetes in Rats Is Angiotensin II- Dependent

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis.

  1999cited by this paper
• Aging and high concentrations of glucose potentiate injury to mitochondrial DNA.

  1999cited by this paper
• Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes.

  1997cited by this paper
• Diabetic Cardiomyopathy: A unique entity or a complication of coronary artery disease?

  1995cited by this paper
• Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats

  1992cited by this paper
• Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen.

  1991cited by this paper
• Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors.

  1991cited by this paper
• Oxidation of glycated proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins.

  1989influential reference
• The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics.

  1981cited by this paper
• Role of diabetes in congestive heart failure: the Framingham study.

  1974cited by this paper

• Vascular protective actions of the angiotensin receptor blockers valsartan and losartan in STZ-induced diabetic rats

  2019influential citation